Akorn Inc. Scores Two Generic Approvals from the FDA

Shares of Lake Forest, Ill.-based Akorn, Inc. jumped more than 12 percent in premarket trading after the company announced two of its generic products were approved by the U.S. Food and Drug Administration (FDA) on Thursday.

The positive announcement offset a five-point loss of company stock drop. Akorn scored approval for a post-operative eye drop and for a generic version of GlaxoSmithKline’s Flonase nasal spray.